Startseite Gene Therapy in PR China: Regulations and Ethical Concerns
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Gene Therapy in PR China: Regulations and Ethical Concerns

  • Xinqing Zhang
Veröffentlicht/Copyright: 9. September 2005
Veröffentlichen auch Sie bei De Gruyter Brill
Journal of international biotechnology law
Aus der Zeitschrift Band 2 Heft 5

Abstract

In 2003, China became the first country in the world to approve a commercial gene therapy product. Yet serious moral doubts have been raised about the conduct of the experiment. The paper examines the ethical issues (e.g. review mechanism, family consent, and therapeutic misconception) in Chinese culture. It argues that China should review the clinical protocols more stringintly. One reason leading to therapeutic misconception is that investigators prefer to use the term ‘gene therapy’ rather than ‘human gene transfer research’ in the consent process. Family consent, from the point of view of the author, is not in itself sufficient to justify the experimental use of patients. Family-based individual consent could be a better option, especially if there are disagreements between a patient and his family in the consent process.

:
Published Online: 2005-09-09
Published in Print: 2005-09-07

Walter de Gruyter GmbH & Co. KG

Heruntergeladen am 23.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jibl.2005.2.5.212/html?lang=de
Button zum nach oben scrollen